Gene silencing in the development of cancer

Experimental Cell Research

Volumn 248, Issue 1, 1999, Pages 25-29

  McBurney, Michael W ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; CANCER GROWTH; CARCINOGENESIS; DNA METHYLATION; GENE INACTIVATION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TUMOR SUPPRESSOR GENE;

ANIMALIA;

EID: 0033541392     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1999.4454     Document Type: Article

References (60)

1. Lengauer C., Kinzler K. W., Vogelstein B. Genetic instabilities in human cancers. Nature. 396:1998;643-649.
2. Pomerantz J., Schreiber-Agus N., Liegeois N. J., Silverman A., Alland L., Chin L., Potes J., Chen K., Orlow I. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2′s inhibition of p53. Cell. 92:1998;713-723.
3. Zhang Y., Xiong Y., Yarbrough W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 92:1998;725-734.
4. Orlando V., Paro R. Chromatin multiprotein complexes involved in the maintenance of transcription patterns. Curr. Opin. Genet. Dev. 5:1995;174-179.
5. van Lohuizen M., Verbeek S., Scheijen B., Wientjens E., van der Gulden H., Berns A. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell. 65:1991;737-752.
6. Haupt Y., Alexander W. S., Barri G., Klinken S. P., Adams J. M. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell. 65:1991;753-763.
7. Haupt Y., Bath M. L., Harris A. W., Adams J. M. bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis. Oncogene. 8:1993;3161-3164.
8. Lee J. T., Jaenisch R. The (epi)genetic control of mammalian X-chromosome inactivation. Curr. Opin. Genet. Dev. 7:1997;274-280.
9. Tilghman S. M. The sins of the fathers and mothers: Genomic imprinting in mammalian development. Cell. 96:1999;185-193.
10. Yun K. Genomic imprinting and carcinogenesis. Histol. Histopathol. 13:1998;425-435.
11. Peterson K., Sapienza C. Imprinting the genome: imprinted genes, imprinting genes, and a hypothesis for their interaction. Annu. Rev Genet. 27:1993;7-31.
12. Meehan R. R., Lewis J. D., Bird A. P. Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Res. 20:1992;5085-5092.
13. Nan X. S., Ng H. H., Johnson C. A., Laherty C. D., Turner B. M., Eisenman R. N., Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature. 393:1998;386-389.
14. Jones P. L., Veenstra G. J. C., Wade P. A., Vermaak D., Kass S. U., Landsberger N., Strouboulis J., Wolffe A. P. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nature Genet. 19:1998;187-191.
15. Lehming N., Le Saux A., Schüller J., Ptashne M. Chromatin components as part of a putative transcriptional repressing complex. Proc. Natl. Acad. Sci. USA. 95:1998;7322-7326.
16. Paterno G. D., Adra C. N., McBurney M. W. X chromosome reactivation in mouse embryonal carcinoma cells. Mol. Cell. Biol. 5:1985;2705-2712.
17. Candido E. P., Reeves R., Davie J. R. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell. 14:1978;105-113.
18. Yoshida M., Kijima M., Akita M., Beppu T. Potent and specific inhibition of mammalian histone deacetylase bothin vivoin vitro. J. Biol. Chem. 265:1990;17174-17179.
19. Kijima M., Yoshida M., Sugita K., Horinouchi S., Beppu T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J. Biol. Chem. 268:1993;22429-22435.
20. Chen W. Y., Bailey E. C., McCune S. L., Dong J. Y., Townes T. M. Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. Proc. Natl. Acad. Sci. USA. 94:1997;5798-5803.
21. Gautsch J. W. Embryonal carcinoma stem cells lack a function required for virus replication. Nature. 285:1980;110.
22. Jahner D., Stuhlmann H., Stewart C. L., Harbers K., Lohler J., Simon I., Jaenisch R. De novo. Nature. 298:1982;623-628.
23. McBurney M. W., Fournier S., Schmidt-Kastner P. K., Jardine K., Craig J. Unstable integration of transfected DNAs into embryonal carcinoma cells. Somatic Cell Mol. Genet. 20:1995;529-540.
24. Schmidt-Kastner P. K., Jardine K., Cormier M., McBurney M. W. Genes transfected into embryonal carcinoma stem cells are both lost and inactivated at high frequency. Somat. Cell Mol. Genet. 22:1996;383-392.
25. Tsukamoto Y., Kato J., Ikeda H. Silencing factors participate in DNA repair and recombination inSaccharomyces cerevisiae. Nature. 388:1997;900-903.
26. Lee Y.-W., Klein C. B., Kargacin B., Salnikow K., Kitahara J., Dowjat K., Zhitkovich A., Christie N. T., Costa M. Carcinogenic nickel silences gene expression by chromatin condensation and DNA methylation: A new model for epigenetic carcinogens. Mol. Cell. Biol. 15:1995;2547-2557.
27. Mass M. J., Wang L. Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: A model for a mechanism of carcinogenesis. Mutat. Res. 386:1997;263-277.
28. Klein C. B., Costa M. DNA methylation, heterochromatin and epigenetic carcinogens. Mutat. Res. 386:1997;163-180.
29. Wu J., Herman J. G., Wilson G., Lee R. Y., Yen R. W., Mabry M., De Bustros A., Nelkin B. D., Baylin S. B. Expression of prokaryotic HhaI DNA methyltransferase is transforming and lethal to NIH 3T3 cells. Cancer Res. 56:1996;616-622.
30. Wu J., Issa J.-P., Herman J., Bassett D. E. Jr., Nelkin B. D., Baylin S. B. Expression of an exogenous eukaryotic DNA methyltransferase gene induces transformation of NIH 3T3 cells. Proc. Natl. Acad. Sci. USA. 90:1993;8891-8895.
31. Laird P. W., Jackson-Grusby L., Fazeli A., Dickinson S. L., Jung W. E., Li E., Weinberg R. A., Jaenisch R. Suppression of intestinal neoplasia by DNA hypomethylation. Cell. 81:1995;197-205.
32. MacLeod A. R., Szyf M. Expression of antisense to DNA methyltransferase mRNA induces DNA demethylation and inhibits tumorigenesis. J. Biol. Chem. 270:1995;8037-8043.
33. Ramchandani S., MacLeod A. R., Pinard M., von Hofe E., Szyf M. Inhibition of tumorigenesis by a cytosine-DNA, methyltransferase, antisense oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA. 94:1997;684-689.
34. Szyf M. Targeting DNA methyltransferase in cancer. Cancer Metastasis Rev. 17:1998;219-231.
35. Siegfried Z., Cedar H. DNA methylation: A molecular lock. Curr. Biol. 7:1997.
36. Galloway D. A., McDougall J. K. Alterations in the cellular phenotype induced by herpes simplex viruses. J. Med. Virol. 31:1990;36-42.
37. Belinsky S. A., Nikula K. J., Palmisano W. A., Michels R., Saccomanno G., Gabrielson E., Baylin S. B., Herman J. G. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl. Acad. Sci. USA. 95:1998;11891-11896.
38. Robertson K. D., Jones P. A. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol. Cell. Biol. 18:1998;6457-6473.
39. Herman J. G., Merlo A., Mao L., Lapidus R. G., Issa J. P. J., Davidson N. E., Sidransky D., Baylin S. B. Inactivation of theCDKN2/p16/MTS1. Cancer Res. 55:1995;4525-4530.
40. Gonzalez-Zulueta M., Bender C. M., Yang A. S., Nguyen T. D., Beart R. W., Van Tornout J. M., Jones P. A. Methylation of the 5′ CpG island of thep16/CDKN2. Cancer Res. 55:1995;4531-4535.
41. Stirzaker C., Millar D. S., Paul C. L., Warnecke P. M., Harrison J., Vincent P. C., Frommer M., Clark S. J. Extensive DNA methylation spanning theRb. Cancer Res. 57:1997;2229-2237.
42. Gouyer V., Gazzeri S., Bolon I., Drevet C., Brambilla C., Brambilla E. Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors. Am. J. Respir. Cell Mol. Biol. 18:1998;188-196.
43. Kanai Y., Ushijima S., Hui A. M., Ochiai A., Tsuda H., Sakamoto M., Hirohashi S. The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Int. J. Cancer. 71:1997;355-359.
44. Hennig G., Behrens J., Truss M., Frisch S., Reichmann E., Birchmeier W. Progression of carcinoma cells is associated with alterations in chromatin structure and factor binding at the E-cadherin promoterin vivo. Oncogene. 11:1995;475-484.
45. Ottaviano Y. L., Issa J. P., Parl F. F., Smith H. S., Baylin S. B., Davidson N. E. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 54:1994;2552-2555.
46. Issa J. P., Ottaviano Y. L., Celano P., Hamilton S. R., Davidson N. E., Baylin S. B. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat. Genet. 7:1994;536-540.
47. Veigl M. L., Kasturi L., Olechnowicz J., Ma A. H., Lutterbaugh J. D., Periyasamy S., Li G. M., Drummond J., Modrich P. L., Sedwick W. D. Biallelic inactivation ofhMLH1. Proc. Natl. Acad. Sci. USA. 95:1998;8698-8702.
48. Kane M. F., Loda M., Gaida G. M., Lipman J., Mishra R., Goldman H., Jessup J. M., Kolodner R. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 57:1997;808-811.
49. Butler L. M., Hewett P. J., Butler W. J., Cowled P. A. Down-regulation of Fas gene expression in colon cancer is not a result of allelic loss or gene rearrangement. Br. J. Cancer. 77:1998;1454-1459.
50. Clifford S. C., Prowse A. H., Affara N. A., Buys C. H., Maher E. R. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes. Cancer. 22:1998;200-209.
51. Herman J. G., Latif F., Weng Y., Lerman M. I., Zbar B., Liu S., Samid D., Duan D. S., Gnarra J. R., Linehan W. M. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA. 91:1994;9700-9704.
52. Qian X., Jin L., Kulig E., Lloyd R. V. DNA methylation regulates p27kip1 expression in rodent pituitary cell lines. Am. J. Pathol. 153:1998;1475-1482.
53. Dodge J. E., List A. F., Futscher B. W. Selective variegated methylation of the p15 CpG island in acute myeloid leukemia. Int. J. Cancer. 78:1998;561-567.
54. Herman J. G., Jen J., Merlo A., Baylin S. B. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res. 56:1996;722-727.
55. Schmidt-Kastner P. K., Jardine K., Cormier M., McBurney M. W. Absence of p53-dependent cell cycle regulation in pluripotent mouse cell lines. Oncogene. 16:1998;3003-3011.
56. Barnas C., Martel-Planche G., Furukawa Y., Hollstein M., Montesano R., Hainaut P. Inactivation of the p53 protein in cell lines derived from human esophageal cancers. Int. J. Cancer. 71:1997;79-87.
57. Habuchi T., Luscombe M., Elder P. A., Knowles M. A. Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. Genomics. 48:1998;277-288.
58. Huynh H., Alpert L., Pollak M. Silencing of the mammary-derived growth inhibitor (MDGI) gene in breast neoplasms is associated with epigenetic changes. Cancer Res. 56:1996;4865-4870.
59. Yu Y., Xu F., Peng H., Fang X., Zhao S., Li Y., Cuevas B., Kuo W. L., Gray J. W., Siciliano M. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc. Natl. Acad. Sci. USA. 96:1999;214-219.
60. Fujii H., Biel M. A., Zhou W., Weitzman S. A., Baylin S. B., Gabrielson E. Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer. Oncogene. 16:1998;2159-2164.